EUROFINS SCIENT Debt to Equity Ratio 2018-2024 | ERFSF
Current and historical debt to equity ratio values for EUROFINS SCIENT (ERFSF) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. EUROFINS SCIENT debt/equity for the three months ending June 30, 2024 was 0.64.
| EUROFINS SCIENT Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-06-30 | $5.92B | $5.70B | 1.04 |
| 2023-06-30 | $5.73B | $5.53B | 1.04 |
| 2022-12-31 | $5.51B | $5.11B | 1.08 |
| 2021-12-31 | $5.51B | $5.53B | 1.00 |
| 2021-06-30 | $5.48B | $4.95B | 1.11 |
| 2020-12-31 | $5.55B | $4.25B | 1.31 |
| 2020-06-30 | $5.08B | $3.83B | 1.33 |
| 2019-12-31 | $5.52B | $3.25B | 1.70 |
| 2019-06-30 | $5.56B | $3.08B | 1.81 |
| 2018-12-31 | $5.30B | $3.22B | 1.65 |
| 2018-06-30 | $4.04B | $3.04B | 1.33 |
| 2017-12-31 | $3.79B | $2.81B | 1.35 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.000B | $7.051B |
| Eurofins Scientific SE provides testing services. The company provides food and feed testing, bioanalytical, biopharma, pharma discovery, pharma early development, pharma central laboratory, biopharma product testing, genomic, agroscience, consumer product testing, forensic, environment testing and REACH services. It operates primarily in Benelux, France, Germany, North America, Nordic countries, the United Kingdom, Ireland and internationally. Eurofins Scientific SE is headquartered in Luxembourg. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $95.766B | 11.88 |
| Cencora (COR) | United States | $49.023B | 18.08 |
| DiDi Global (DIDIY) | China | $23.330B | 0.00 |
| ICON (ICLR) | Ireland | $17.511B | 15.60 |
| Natera (NTRA) | United States | $16.712B | 0.00 |
| Viatris (VTRS) | United States | $15.433B | 4.75 |
| Avantor (AVTR) | United States | $14.831B | 22.24 |
| Revvity (RVTY) | United States | $14.647B | 25.44 |
| BioMerieux (BMXMF) | France | $12.894B | 0.00 |
| CochLear (CHEOY) | Australia | $12.739B | 0.00 |
| Solventum (SOLV) | United States | $12.214B | 0.00 |
| Medpace Holdings (MEDP) | United States | $11.215B | 31.59 |
| Charles River Laboratories (CRL) | United States | $11.042B | 21.34 |
| Doximity (DOCS) | United States | $10.778B | 63.79 |
| HealthEquity (HQY) | United States | $8.750B | 47.49 |
| Sonic Healthcare (SKHHY) | Australia | $8.450B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.881B | 32.03 |
| Life Times (LTH) | United States | $5.005B | 33.12 |
| Sotera Health (SHC) | United States | $4.402B | 23.55 |
| Organon (OGN) | United States | $4.012B | 4.05 |
| Surgery Partners (SGRY) | United States | $3.759B | 42.85 |
| BrightSpring Health Services (BTSG) | United States | $3.402B | 72.37 |
| PACS (PACS) | United States | $3.129B | 0.00 |
| Concentras Parent (CON) | United States | $2.579B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.523B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.446B | 0.00 |
| Premier (PINC) | United States | $2.301B | 11.48 |
| GeneDx Holdings (WGS) | United States | $2.113B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $2.036B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.783B | 47.00 |
| Teladoc Health (TDOC) | United States | $1.670B | 0.00 |
| Progyny (PGNY) | United States | $1.551B | 29.62 |
| Pediatrix Medical (MD) | United States | $1.331B | 13.02 |
| CareDx (CDNA) | United States | $1.251B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.184B | 0.00 | |
| AMN Healthcare Services Inc (AMN) | United States | $0.993B | 6.72 |
| Embecta (EMBC) | United States | $0.898B | 5.99 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| InnovAge Holding (INNV) | United States | $0.778B | 0.00 |
| Agilon Health (AGL) | United States | $0.770B | 0.00 |
| SBC Medicals (SBC) | United States | $0.717B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.510B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.442B | 0.00 |
| DocGo (DCGO) | United States | $0.426B | 16.00 |
| Enhabit (EHAB) | United States | $0.383B | 33.09 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.346B | 0.00 |
| LifeMD (LFMD) | United States | $0.310B | 0.00 |
| ModivCare (MODV) | United States | $0.244B | 13.24 |
| Sera Prognostics (SERA) | United States | $0.242B | 0.00 |
| Beauty Health (SKIN) | United States | $0.211B | 0.00 |
| Nutex Health (NUTX) | United States | $0.204B | 0.00 |
| Biodesix (BDSX) | United States | $0.204B | 0.00 |
| MultiPlan (MPLN) | United States | $0.141B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.120B | 0.00 |
| So-Young (SY) | China | $0.073B | 17.77 |
| Singular Genomics Systems (OMIC) | United States | $0.057B | 0.00 |
| Harvard Apparatus Regenerative Technology (HRGN) | United States | $0.054B | 0.00 |
| OncoCyte (OCX) | United States | $0.051B | 0.00 |
| NeueHealth (NEUE) | United States | $0.042B | 1.12 |
| Co-Diagnostics (CODX) | United States | $0.037B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.029B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.027B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.027B | 0.00 |
| Oncology Institute (TOI) | United States | $0.022B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| XWELL (XWEL) | United States | $0.009B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| KindlyMD (KDLY) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |